Contact
searchSearch
HMP Global
Login

Breast Cancer

.st0 {fill: #000;}
Rebecca Shatsky, MD, University of California, San Diego
Videos
Datopotamab Deruxtecan Plus Durvalumab for Certain Patients With Advanced Breast Cancer
06/07/2024
Rebecca Shatsky, MD, shares results on datopotamab deruxtecan plus durvalumab for certain patients with advanced breast cancer from the I-SPY2.2 trial.
Rebecca Shatsky, MD, shares results on datopotamab deruxtecan plus durvalumab for certain patients with advanced breast cancer from the I-SPY2.2 trial.
Rebecca Shatsky, MD, shares...
06/07/2024
Oncology
.st0 {fill: #000;}
Dr Linden
Videos
Dr Linden Discusses the AMEERA-1 Study in ER+, HER2- Metastatic Breast Cancer
07/01/2021
Hannah Linden, MD, discusses a phase 1/2 study of amcenestrant plus palbociclib for postmenopausal women with ER-positive/HER2-negative metastatic breast cancer.
Hannah Linden, MD, discusses a phase 1/2 study of amcenestrant plus palbociclib for postmenopausal women with ER-positive/HER2-negative metastatic breast cancer.
Hannah Linden, MD, discusses a...
07/01/2021
Oncology
.st0 {fill: #000;}
Videos
Enobosarm Displays Clinical Benefit in AR+, ER+ Breast Cancer
06/30/2021
Hannah Linden, MD, highlights the efficacy of enobosarm in patients with advanced AR/ER-positive breast cancer. These data were presented at the 2021 ASCO Annual Meeting.
Hannah Linden, MD, highlights the efficacy of enobosarm in patients with advanced AR/ER-positive breast cancer. These data were presented at the 2021 ASCO Annual Meeting.
Hannah Linden, MD, highlights...
06/30/2021
Oncology
.st0 {fill: #000;}
Dr Harbeck
Videos
Dr Harbeck Talks Pertuzumab Plus Trastuzumab in HR-/HER2+ Early Breast Cancer
06/07/2021
Nadia Harbeck, MD, PhD, discusses results from the ADAPT-HR-/HER2+ trial on early breast cancer.
Nadia Harbeck, MD, PhD, discusses results from the ADAPT-HR-/HER2+ trial on early breast cancer.
Nadia Harbeck, MD,...
06/07/2021
Oncology
.st0 {fill: #000;}
Videos
Mridula George, MD, Talks Neoadjuvant TALA in gBRCA1/2 Mutation-Positive, Early HER2-Negative Breast Cancer
05/01/2021
Mridula George, MD, discusses the results following the phase 2 study of neoadjuvant talazoparib in patients with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer, presented at the virtual 2021 American Society...
Mridula George, MD, discusses the results following the phase 2 study of neoadjuvant talazoparib in patients with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer, presented at the virtual 2021 American Society...
Mridula George, MD, discusses...
05/01/2021
Oncology
.st0 {fill: #000;}
Cisplatin–Veliparib Combo Significantly Improves PFS in Advanced TNBC
Videos
Cisplatin–Veliparib Combo Significantly Improves PFS in Advanced TNBC
06/07/2020
Julie Gralow, MD, discusses the findings of the phase 2 SWOG S1416 trial.
Julie Gralow, MD, discusses the findings of the phase 2 SWOG S1416 trial.
Julie Gralow, MD, discusses the...
06/07/2020
Oncology
.st0 {fill: #000;}
Julie Gralow, MD, Talks HER2+ Breast Cancer and the KAITLIN Clinical Trial
Videos
Julie Gralow, MD, Talks HER2+ Breast Cancer and the KAITLIN Clinical Trial
05/29/2020
Dr Gralow discusses the primary findings of the phase 3 KAITLIN study, in which side effects outweighed the efficacy of adjuvant trastuzumab emtansine for early HER2-positive breast cancer.
Dr Gralow discusses the primary findings of the phase 3 KAITLIN study, in which side effects outweighed the efficacy of adjuvant trastuzumab emtansine for early HER2-positive breast cancer.
Dr Gralow discusses the primary...
05/29/2020
Oncology
.st0 {fill: #000;}
Experts Identify Risks for AI Nonadherence in Patients With Breast Cancer
Videos
Experts Identify Risks for AI Nonadherence in Patients With Breast Cancer
05/27/2020
Julie Gralow, MD, talks about how she and her co-investigators identified baseline risk factors associated with increases in AI nonadherence in patients with breast cancer.
Julie Gralow, MD, talks about how she and her co-investigators identified baseline risk factors associated with increases in AI nonadherence in patients with breast cancer.
Julie Gralow, MD, talks about...
05/27/2020
Oncology
.st0 {fill: #000;}
Ongoing Trial Will Assess Trastuzumab Deruxtecan–Pembrolizumab Combo for Breast Cancer, NSCLC
Videos
Ongoing Trial Will Assess Trastuzumab Deruxtecan–Pembrolizumab Combo for Breast Cancer, NSCLC
05/27/2020
Hope Rugo, MD, looks forward to the safety and efficacy findings of an ongoing study examining trastuzumab deruxtecan plus pembrolizumab for breast cancer and NSCLC.
Hope Rugo, MD, looks forward to the safety and efficacy findings of an ongoing study examining trastuzumab deruxtecan plus pembrolizumab for breast cancer and NSCLC.
Hope Rugo, MD, looks forward to...
05/27/2020
Oncology
.st0 {fill: #000;}
Alpelisib–Fulvestrant Combo May Benefit PIK3CA+ Breast Cancer Progressing With CDK Inhibitors
Videos
Alpelisib–Fulvestrant Combo May Benefit PIK3CA+ Breast Cancer Progressing With CDK Inhibitors
05/27/2020
Hope S. Rugo, MD, discusses the clinical significance of the ongoing BYLieve trial.
Hope S. Rugo, MD, discusses the clinical significance of the ongoing BYLieve trial.
Hope S. Rugo, MD, discusses the...
05/27/2020
Oncology
.st0 {fill: #000;}
Conference Insider
Tucatinib Plus Trastuzumab and Capecitabine Exhibits Tolerable Safety in HER2+ Breast Cancer
05/26/2020
Tucatinib plus trastuzumab and capecitabine was shown to be well-tolerated in the HER2CLIMB trial of patients with HER2-positive breast cancer.
Tucatinib plus trastuzumab and capecitabine was shown to be well-tolerated in the HER2CLIMB trial of patients with HER2-positive breast cancer.
Tucatinib plus trastuzumab and...
05/26/2020
Oncology
.st0 {fill: #000;}
Conference Insider
Liposomal Mitoxantrone Shows Promise in Patients With Advanced Breast Cancer
05/26/2020
Liposomal mitoxantrone led to improvements in ORR, DCR, and PFS when compared with mitoxantrone hydrochloride injection in patients with advanced breast cancer.
Liposomal mitoxantrone led to improvements in ORR, DCR, and PFS when compared with mitoxantrone hydrochloride injection in patients with advanced breast cancer.
Liposomal mitoxantrone led to...
05/26/2020
Oncology
.st0 {fill: #000;}
Conference Insider
Real-World Clinical Study Supports Use of Olaparib for Metastatic Breast Cancer
05/26/2020
Interim findings from a real-world study support using olaparib as an alternative to chemo in patients with HER2-negative metastatic breast cancer with germline BRCA mutations.
Interim findings from a real-world study support using olaparib as an alternative to chemo in patients with HER2-negative metastatic breast cancer with germline BRCA mutations.
Interim findings from a...
05/26/2020
Oncology
.st0 {fill: #000;}
Conference Insider
Factors of Therapy Delivery Tied to Adherence in Nonmetastatic Breast Cancer
05/26/2020
The method by which adjuvant endocrine therapy is delivered to patients with breast cancer is associated with rate of adherence.
The method by which adjuvant endocrine therapy is delivered to patients with breast cancer is associated with rate of adherence.
The method by which adjuvant...
05/26/2020
Oncology
.st0 {fill: #000;}
Conference Insider
Maintenance Metronomic Capecitabine Extends DFS in TNBC
05/26/2020
One year of maintenance metronomic capecitabine after standard treatment significantly improves DFS in patients with operable TNBC.
One year of maintenance metronomic capecitabine after standard treatment significantly improves DFS in patients with operable TNBC.
One year of maintenance...
05/26/2020
Oncology
.st0 {fill: #000;}
Podcasts
Adding Ribociclib to Endocrine Therapy Improves OS in Young Patients With Advanced Breast Cancer
06/19/2019
Sara A. Hurvitz, MD, discusses the background, findings, and clinical significance of the MONALEESA 7 trial.
Sara A. Hurvitz, MD, discusses the background, findings, and clinical significance of the MONALEESA 7 trial.
Sara A. Hurvitz, MD, discusses...
06/19/2019
Oncology
.st0 {fill: #000;}
Videos
Margetuximab Plus Chemo Improves PFS in HER2-Positive, Metastatic Breast Cancer
06/10/2019
Hope S. Rugo, MD, discusses the clinical significance of the phase 3 SOPHIA trial, the findings of which were presented at ASCO 2019.
Hope S. Rugo, MD, discusses the clinical significance of the phase 3 SOPHIA trial, the findings of which were presented at ASCO 2019.
Hope S. Rugo, MD, discusses the...
06/10/2019
Oncology
.st0 {fill: #000;}
Pathologic Analysis of HER2 Heterogeneity Predicts Responses to Therapy in Breast Cancer
05/29/2019
Study findings to be presented at ASCO 2019 show that ITH-HER2 evaluated routinely via pathology is a strong prognosticator of pathologic complete response to dual-HER2 targeted therapy.
Study findings to be presented at ASCO 2019 show that ITH-HER2 evaluated routinely via pathology is a strong prognosticator of pathologic complete response to dual-HER2 targeted therapy.
Study findings to be presented...
05/29/2019
Oncology
.st0 {fill: #000;}
Pembrolizumab Active in Heavily Pretreated Metastatic Breast Cancer With High TMB
05/29/2019
Pembrolizumab demonstrated anti-tumor activity in heavily pretreated patients with metastatic breast cancer and a high TMB in a recent phase 2 study being presented at ASCO 2019.
Pembrolizumab demonstrated anti-tumor activity in heavily pretreated patients with metastatic breast cancer and a high TMB in a recent phase 2 study being presented at ASCO 2019.
Pembrolizumab demonstrated...
05/29/2019
Oncology
.st0 {fill: #000;}
OS Benefit of Atezolizumab Plus Nab-Paclitaxel for Triple-Negative Breast Cancer Confirmed
05/29/2019
Findings to be presented at ASCO 2019 confirm the OS benefit of using atezolizumab plus nab-paclitaxel in treatment-naïve patients with PD-L1–positive, metastatic triple-negative breast cancer.
Findings to be presented at ASCO 2019 confirm the OS benefit of using atezolizumab plus nab-paclitaxel in treatment-naïve patients with PD-L1–positive, metastatic triple-negative breast cancer.
Findings to be presented at ASCO...
05/29/2019
Oncology

About the ASCO Annual Meeting

Experts from across the globe gather to discover and share groundbreaking research among members of the cancer care community who diagnose, treat, and study patients with multiple types of cancer.

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use